Novartis’ biosimilars and generics arm Sandoz has struck a deal with Polpharma Biologics to market a proposed biosimilar of Biogen’s multiple sclerosis drug Tysabri (natalizumab).<
Sandoz is to appeal a court decision preventing it from launching a cheaper biosimilar competitor to Amgen’s Enbrel (etanercept) inflammatory diseases drug in the US, three years after appr
We speak to Sandoz’s global head of biopharmaceuticals, Stefan Hendriks, about the remaining challenges in market access for biosimilars and what the future could hold for this still-bu
In this issue of Deep Dive we explore the ever present issues of market access and commercialisation, analysing recent changes in China, England and the US and asking how pharma can work with he
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.